Ernst & Young endorses Oncolytics Biotech's key disclosures
Ernst & Young LLP reviewed and agreed with specific management statements in the July 8-K concerning financial condition. The auditor provides third-party verification of the MD&A prior to the SEC's review period.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day